The word biohacking appears everywhere now. On supplement labels, in podcast titles, across social media feeds, and in the marketing copy of companies selling everything from red light panels to peptide protocols. The term has expanded so far beyond its original meaning that it now functions less as a descriptor and more as a signal: this product is for people who take their biology seriously. Whether the underlying science supports that signal is a different question entirely, and it is one the wellness industry has a poor track record of answering honestly. Companies like Next Gen Peptides operate in this space with a research-first positioning that reflects where the science actually is rather than where the marketing wants it to be. But understanding why the gap between claims and evidence exists in the first place is useful for anyone trying to navigate this category intelligently.
What Biohacking Actually Means
The term biohacking emerged from a community of self-experimenters in the early 2010s who were interested in using measurable data and systematic experimentation to optimize their own biology. The original ethos was genuinely scientific in spirit: form a hypothesis, test an intervention, track outcomes, iterate. Dave Asprey, Tim Ferriss, and others popularized this approach through their own public self-experimentation, and the community that grew around it was characterized by a genuine commitment to evidence, however informal.
What the term refers to today is considerably broader and considerably less rigorous. Biohacking now encompasses everything from sleep tracking and cold exposure to peptide protocols, NAD+ supplementation, GLP-1 analogues, and mitochondrial support compounds. Some of these interventions have strong mechanistic rationales and meaningful preliminary research behind them. Others are riding the credibility of the category without contributing much to it.
The problem is not that the interventions are categorically invalid. Many are genuinely interesting and some are well-supported by early research. The problem is that the marketing claims attached to them routinely outrun the evidence, and consumers who are not trained to read research have very little practical way to tell the difference.
How the Science Gap Develops
The gap between what a compound actually does in research settings and what a brand claims it does is not always the result of deliberate deception. It develops through a series of compounding distortions that each seem individually defensible but collectively produce significant misrepresentation.
The first distortion happens at the research-to-media translation step. A study shows that a peptide reduces inflammation markers in a rodent model under specific conditions. A science journalist summarizes this as the peptide fighting inflammation. A wellness blogger reads the summary and writes that the peptide is a powerful anti-inflammatory. A supplement brand reads the blog post and puts anti-inflammatory on their label. By the time the finding reaches the consumer, its context has been stripped away entirely.
The second distortion is the species problem. A significant portion of the research supporting biohacking compounds has been conducted in animal models, primarily rodents. Animal studies are valuable for identifying mechanisms and generating hypotheses, but they are a poor basis for making specific outcome claims in humans. Biology is not uniformly conserved across species, dosing relationships differ substantially, and many promising animal study results have failed to replicate in human trials. The wellness industry routinely presents rodent study findings as if they were human clinical data.
The third distortion is the dose and context problem. Research findings are almost always dose-specific and context-specific. A compound that produces measurable effects at a particular dose in a particular population under particular conditions may produce no effect, a different effect, or an adverse effect at a different dose, in a different population, under different conditions. Marketing claims almost never include this context because it makes the claim less compelling.
Why Consumers Struggle to Evaluate Claims
The average consumer navigating the biohacking space is working with a real information disadvantage that the industry does not try very hard to correct.
Reading a primary research paper requires familiarity with study design, statistical literacy, and enough domain knowledge to evaluate whether the methodology is appropriate to the question being asked. Most people do not have this. They rely on summaries, reviews, and recommendations from sources they trust, which means their evaluation of any given claim is heavily dependent on the quality of the intermediaries they rely on.
The incentive structure of those intermediaries is not uniformly aligned with accuracy. A podcaster who takes sponsorship money from a peptide company has a different incentive than an independent researcher reviewing the same evidence. An influencer compensated for promoting a nootropic stack has a different incentive than a pharmacologist with no financial relationship to the product. This does not mean sponsored content is automatically wrong, but it does mean the claims it produces should be weighted accordingly.
The regulatory environment adds another layer of complexity. In the US, the supplement industry operates under a framework that allows companies to make structure or function claims without clinical trial evidence, provided they include a disclaimer noting the claim has not been evaluated by the FDA. The practical effect of this is that consumers regularly encounter confidently stated claims that carry essentially no regulatory burden of proof.
The Research Compound Framework
One of the more honest approaches to this problem is the research compound model, which is how suppliers like NextGen Peptides frame their product category. Research peptides and compounds are positioned explicitly as materials for scientific inquiry rather than as consumer health products with clinical outcome guarantees.
This framing matters because it accurately represents where most of these compounds actually are in their development trajectory. BPC-157, TB-500, Epithalon, Semax, and the other peptides in this category have generated genuinely interesting research. Some have decades of investigation behind them. But they have not completed the clinical trial pipeline that would justify broad therapeutic claims. They are at the stage where serious researchers want access to high-purity, independently tested material to study further, not at the stage where manufacturers should be making outcome promises to consumers.
NextGen Peptides emphasizes 99 percent purity and independent third-party lab testing across its product range, with a COA library available for verification. This kind of transparency is meaningful in a space where purity and concentration claims from suppliers are inconsistently reliable. A researcher or serious self-experimenter working with a compound needs to know what is actually in the vial, and third-party verification is the only way to establish that with confidence.
Compounds Worth Understanding in Context
Several of the compounds that generate significant interest in the biohacking space have enough research behind them that a nuanced evaluation is possible, even if definitive clinical claims are not.
BPC-157 is a synthetic peptide derived from a protein found in gastric juice. It has been studied extensively in animal models for its effects on tissue repair, gut integrity, and inflammation modulation. The mechanistic picture is coherent and the animal data is substantial. Human clinical data is limited, which is why honest positioning treats it as a research compound rather than a therapeutic product.
NAD+ precursors and direct NAD+ supplementation have attracted significant research interest because of NAD+’s central role in cellular energy metabolism and its relationship to aging biology. The science here is more developed than in many other biohacking categories, with human trials showing measurable effects on NAD+ levels from supplementation. What those elevated levels translate to in terms of health outcomes over the long term remains an active research question.
Nootropic compounds including Semax and Pinealon have research histories primarily in Eastern European clinical settings, which creates some evaluation challenges because the literature is less integrated into Western research databases. The mechanistic rationales are plausible and the compounds have been used in clinical contexts in Russia and Ukraine for decades, but the evidence base looks different from what a Western clinical trial infrastructure would produce.
What a More Honest Framework Looks Like
The biohacking industry does not need to stop making any claims. It needs to make claims that accurately represent the state of the evidence.
A more honest framework distinguishes consistently between mechanistic plausibility, animal study data, preliminary human data, and robust clinical evidence. It acknowledges when a compound’s human research is limited without dismissing the underlying rationale. It provides transparent information about purity, testing methodology, and sourcing. And it positions products accurately within the research and development stage they actually occupy rather than implying clinical validation that does not exist.
Consumers who approach this space with that framework, asking what kind of evidence supports this claim, in what context was it established, and how does the product’s positioning align with that evidence, are in a much better position to make decisions that reflect the actual state of the science rather than the state of the marketing.
The science gap in the wellness industry is not going to close itself. The incentives that created it are too durable and the information asymmetry is too convenient for the parties who benefit from it. What can change is how individual consumers evaluate claims, and that starts with understanding why the gap exists in the first place.
- About the Author
- Latest Posts
Our Editorial Team are writers and experts in their field. Their views and opinions may not always be the views of Wellbeing Magazine. If you are under the direction of medical supervision please speak to your doctor or therapist before following the advice and recommendations in these articles.
